Cargando…

CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas

We aimed to elucidate the diagnostic potential of the C-X-C motif chemokine receptor 4 (CXCR4)-directed positron emission tomography (PET) tracer (68)Ga-Pentixafor in patients with poorly differentiated neuroendocrine carcinomas (NEC), relative to the established reference standard (18)F-FDG PET/com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weich, Alexander, Werner, Rudolf A., Buck, Andreas K., Hartrampf, Philipp E., Serfling, Sebastian E., Scheurlen, Michael, Wester, Hans-Jürgen, Meining, Alexander, Kircher, Stefan, Higuchi, Takahiro, Pomper, Martin G., Rowe, Steven P., Lapa, Constantin, Kircher, Malte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067200/ https://www.ncbi.nlm.nih.gov/pubmed/33805264 http://dx.doi.org/10.3390/diagnostics11040605

Ejemplares similares

CXCR4-Directed Imaging in Solid Tumors
por: Werner, Rudolf A., et al.
Publicado: (2019)

The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
por: Werner, Rudolf A., et al.
Publicado: (2018)

Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
por: Serfling, Sebastian E., et al.
Publicado: (2022)

CXCR4-directed theranostics in oncology and inflammation
por: Kircher, Malte, et al.
Publicado: (2018)

Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [(68)Ga] Pentixafor Internalization in Neuroendocrine Tumor Cells
por: Weich, Alexander, et al.
Publicado: (2021)

Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4–Directed Molecular Imaging and Therapy
por: Hartrampf, Philipp E., et al.
Publicado: (2023)

Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach
por: Werner, Rudolf A., et al.
Publicado: (2017)

Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers
por: Weich, Alexander, et al.
Publicado: (2022)

Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging
por: Kosmala, Aleksander, et al.
Publicado: (2023)

Investigation of spleen CXCR4 expression by [(68)Ga]Pentixafor PET in a cohort of 145 solid cancer patients
por: Lewis, Richard, et al.
Publicado: (2021)

Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer
por: Serfling, Sebastian E., et al.
Publicado: (2023)

In-Vivo Somatostatin-Receptor Expression in Small Cell Lung Cancer as a Prognostic Image Biomarker and Therapeutic Target
por: Şen, Feyza, et al.
Publicado: (2023)

CXCR4-targeted molecular imaging after severe SARS-Cov-2 infection
por: Lambertini, Alessandro, et al.
Publicado: (2022)

Impact of (68)Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors
por: Kosmala, Aleksander, et al.
Publicado: (2023)

Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
por: Linz, Christian, et al.
Publicado: (2021)

Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission Tomography
por: Kosmala, Aleksander, et al.
Publicado: (2022)

The impact of (177)Lu-octreotide therapy on (99m)Tc-MAG3 clearance is not predictive for late nephropathy
por: Werner, Rudolf A., et al.
Publicado: (2016)

Novel Noninvasive Nuclear Medicine Imaging Techniques for Cardiac Inflammation
por: Kircher, Malte, et al.
Publicado: (2017)

Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors
por: Kosmala, Aleksander, et al.
Publicado: (2023)

[(68)Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas
por: Breun, Maria, et al.
Publicado: (2019)

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma
por: Lapa, Constantin, et al.
Publicado: (2017)

High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors—A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures
por: Marquardt, André, et al.
Publicado: (2023)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
por: Lapa, Constantin, et al.
Publicado: (2017)

The next era of renal radionuclide imaging: novel PET radiotracers
por: Werner, Rudolf A., et al.
Publicado: (2019)

Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications
por: Werner, Rudolf A., et al.
Publicado: (2018)

Somatostatin Receptor–Directed PET/CT Can Differentiate Between Different Subtypes of Head and Neck Paragangliomas
por: Zhi, Yingjun, et al.
Publicado: (2023)

Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor–Directed Molecular Imaging and Therapy
por: Serfling, Sebastian E., et al.
Publicado: (2022)

The Number of Frames on ECG-Gated (18)F-FDG Small Animal PET Has a Significant Impact on LV Systolic and Diastolic Functional Parameters
por: Eissler, Christoph, et al.
Publicado: (2021)

Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT
por: Mihatsch, Patrick W., et al.
Publicado: (2022)

Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease
por: Fröhlich, Matthias, et al.
Publicado: (2021)

SUV(mean) on baseline [(18)F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2023)

Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [(177)Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome
por: Hartrampf, Philipp E., et al.
Publicado: (2021)

Pitfalls in PSMA-PET/CT: intensive bone marrow uptake in a case with polycythemia vera
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

Sarcoid-like reactions: a potential pitfall in oncologic imaging
por: Gebrekidan, Selamawit, et al.
Publicado: (2020)

(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

Granulomatous dermatitis: a rare pitfall in lymphoma staging with [(18)F]FDG-PET/CT
por: Enke, Johanna S., et al.
Publicado: (2023)

Molecular Imaging-Derived Biomarker of Cardiac Nerve Integrity — Introducing High NET Affinity PET Probe (18)F-AF78
por: Chen, Xinyu, et al.
Publicado: (2022)

In Vivo Functional Assessment of Sodium-Glucose Cotransporters (SGLTs) Using [(18)F]Me4FDG PET in Rats
por: Matsusaka, Yohji, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cjqec7jp7kgdhr1kgvetsnujoq